Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) fell 7.6% during trading on Friday . The company traded as low as $4.82 and last traded at $4.80. 76,086 shares were traded during trading, a decline of 95% from the average session volume of 1,385,886 shares. The stock had previously closed at $5.19.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on VIR. The Goldman Sachs Group decreased their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 price target on shares of Vir Biotechnology in a research note on Thursday, May 22nd. Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.86.
View Our Latest Stock Report on Vir Biotechnology
Vir Biotechnology Stock Up 3.3%
The firm's 50 day simple moving average is $5.47 and its 200-day simple moving average is $7.48. The company has a market capitalization of $723.68 million, a PE ratio of -1.34 and a beta of 1.36.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $3.03 million for the quarter, compared to analysts' expectations of $8.59 million. During the same period last year, the company posted ($0.48) earnings per share. The firm's revenue for the quarter was down 94.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.
Insider Activity at Vir Biotechnology
In related news, CEO Backer Marianne De sold 79,712 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares of the company's stock, valued at approximately $4,578,554.75. This represents a 9.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 16.00% of the company's stock.
Hedge Funds Weigh In On Vir Biotechnology
Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in shares of Vir Biotechnology during the first quarter valued at about $335,000. Focus Partners Wealth increased its stake in Vir Biotechnology by 15.3% during the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company's stock valued at $125,000 after buying an additional 2,566 shares during the period. SCS Capital Management LLC bought a new stake in shares of Vir Biotechnology during the 1st quarter worth about $157,000. Woodline Partners LP raised its position in shares of Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company's stock worth $3,024,000 after buying an additional 331,701 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock worth $4,813,000 after acquiring an additional 225,544 shares during the period. 65.32% of the stock is owned by institutional investors.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
See Also
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
